VEEVA SYSTEMS INC - SaaS Valuation Profile VEEV

Veeva Systems is the leading cloud software provider for the global life sciences industry. It serves pharmaceutical companies, biotech firms, contract research organizations, and medical device manufacturers. Peter Gassner, a former Salesforce executive, founded it in 2007 in Pleasanton, California, with a singular focus on becoming the technology backbone for life sciences.

Two product families drive the business. Veeva Commercial Cloud provides CRM and commercial data solutions for pharma sales and marketing teams. Originally built on Salesforce, Veeva CRM was the first cloud CRM tailored for pharmaceutical companies. It lets drug reps manage healthcare provider relationships, track samples, and access medical content while staying compliant with industry regulations. The company is now transitioning to Vault CRM, built on its own platform, which eliminates the dependency on Salesforce infrastructure.

Veeva Vault is the core technology platform. It's a unified cloud content management and data platform purpose-built for regulated industries. Vault applications cover the entire drug development lifecycle: Clinical for data management and trial master files, RIM for regulatory submissions, Quality for quality management and document control, Safety for pharmacovigilance, and Medical for medical affairs. All Vault applications share a common data model and workflow engine, cutting integration complexity.

Veeva also offers master data solutions through Network for customer and product reference data, and Compass for patient and prescriber data.

Penetration of the top 20 pharma companies is approaching 100%. Growth comes from driving adoption of additional Vault applications within existing customers and capturing smaller biotech companies.

The revenue model blends subscriptions and professional services, with subscriptions exceeding 80% of the roughly $2.5 billion in annual revenue. Gross margins sit around 74%. Operating margins run near 40%, making Veeva one of the most profitable companies in enterprise SaaS. Net revenue retention consistently stays above 115%.

In 2021, Veeva made an unusual move and converted to a Public Benefit Corporation. This commits the company to balancing shareholder value with the interests of customers, employees, and the life sciences industry. With about 7,000 employees and deep regulatory expertise, Veeva has built a nearly unassailable position as the dominant vertical SaaS platform in life sciences.